首页> 外文会议>International Pharmaceutical Symposium >Study on new ocular drug delivery system
【24h】

Study on new ocular drug delivery system

机译:新型眼药递送系统研究

获取原文

摘要

Ophthalmic drug delivery is one of the important fields of controlled release. The sensitivity and protection mechanism of eye promote more effective drug delivery system with better compliancy to be developed, however, the application of numerous pharmaceutical method are limited simultaneously, which presents great challenge in designing ocular dosage form. In recent years, liposome, nanoparticles, microspheres and microemulsion have received extensive interests.Cationic liposome is a novel drug delivery system in recent years and mainly used as a vector for gene-therapeutic drugs. Because of the electrostatic interaction between the positive charges on the lipid vesicle and the negative charges on surface of the cornea, the cationic liposome can raise the drug's corneal retention time, corneal permeability and bioavailability when used for the treatment of ocular diseases. Solid lipid nanoparticle is developed at early 1990s, now it is a good alternative carrier of traditional colloidal controlled-release drug delivery system. It has many advantages such as good biocompatibility duo to the use of physiological and biodegradable lipids of low systemic toxicity, possibility of production on large industrial and reduce of drug leakage during storage. Some people report that solid lipid nanoparticle drug delivery system can improve ocular bioavailability. Micro emulsion is defined as a dispersion consist of oil, surfactant, cosurfactant and aqueous. Micro emulsion has several advantages such as enhanced drug solubility, good thermodynamic stability, enhancing effect on transdermal ability over conventional formulation.The purpose of this article was to study the preparations and the in vitro release of cationic liposomes, solid lipid nanopaticles and micro emulsion ocular drug delivery system. Ibuprofen was used as a model drug of highly lipophilic. In this work, DC-Chol was synthesized by N', N'-dimethylethylene diamine and cholesterol chloroformate and used as positively charging material in cationic liposome formulation. The Ibuprofen cationic liposome, Ibuprofen solid lipid nanoparticles and Ibuprofen microemulsion were prepared by ethanol-injecting method and melting-ultrasonic method, respectively. The physical-chemical properties such as entrapping efficiency, particle size and zeta potential of the three preparations were characterized and the isolated cornea permeability tests were carried out to reveal the in vitro release of them; The entrapping efficiency of lbuprofen cationic liposome and Ibuprofen solid lipid nanoparticles were 78.3% and 92.5%; particle size and zeta potential of cationic liposome, solid lipid nanoparticles and microemulsion were 163nm, 69nm, 80nm and +44.7mv, -20.2mv, +35. 1mv; the Papp of four test preparations, Ibuprofen cationic liposome, solid lipid nanoparticles, micro emulsion, solid lipid nanoparticles with 0.02% Transcutle P as permeability enhancer were 5.44, 5.51, 4.59 and 6.35 fold in contrast with Ibuprofen eye drops (suspension).All the three microparticles ophthalmic drug delivery systems studied showed no significant irrigation to rabbit eyes and could enhance the isolated corneal permeability of model drug.
机译:眼科药物递送控制释放的一个重要领域。眼的灵敏度和保护机制,促进更有效的药物输送系统具有更好的合规性进行开发,然而,许多制药方法的应用被同时限制,这会在设计眼剂型巨大的挑战。近年来,脂质体,纳米颗粒,微球和微乳液已经得到了广泛的interests.Cationic脂质体是一种新的药物递送系统在近年来并主要用作基因治疗药物的载体。因为在脂质囊泡和正电荷在角膜的表面上的负电荷之间的静电相互作用的,用于眼部疾病的治疗中时,阳离子脂质体可以提高药物的角膜的保留时间,角膜通透性和生物利用度。固体脂质纳米粒是在20世纪90年代初开发的,现在则是传统的胶体控释给药系统的一个很好的替代载体。它有许多优点,如良好的生物相容性哆来使用大型工业低全身性毒性,生产的可能性的生理和生物可降解脂质的和储存期间药物渗漏的减少。有人报告说,固体脂质纳米粒给药系统可以提高眼部生物利用度。微乳液的定义是分散包括油,表面活性剂,助表面活性剂和水。微乳液具有几个优点,例如增强的药物的溶解度,良好的热稳定性,从而增强对经皮能力超过了本文的常规formulation.The目的效果是研究制剂和阳离子脂质体的体外释放,固体脂质纳米粒和微乳液眼药物递送系统。布洛芬作为高度亲脂性的模型药物。在这项工作中,DC-澈用N”,N'-二甲基乙二胺和胆固醇氯甲酸酯合成,被用作在阳离子脂质体制剂带正电的材料。的布洛芬阳离子性脂质体,布洛芬固体脂质纳米颗粒和布洛芬微乳由分别乙醇注入法和熔融超声波法制备。物理 - 化学性质,例如截留效率,颗粒大小和三种制剂的ζ电位进行了表征和分离角膜渗透性进行了试验,以揭示它们的体外释放;布洛芬阳离子脂质体和布洛芬固体脂质纳米颗粒的包封效率分别为78.3%和92.5%;粒径和阳离子脂质体的zeta电位,固体脂质纳米颗粒和微滴乳状液是163nm,69nm,80nm的和+ 44.7mv,-20.2mv,35。 1mV的;四个测试制剂,布洛芬阳离子脂质体,固体脂质纳米颗粒,微乳剂,固体脂质纳米颗粒中,PAPP 0.02%Transcutle数p作为通透性增强剂是5.44,5.51,4.59和6.35倍与布洛芬滴眼液(悬浮液)对比。所有的3个微粒眼科给药系统研究了没有表现出显著灌溉兔眼,并可能提高模型药物的分离角膜通透性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号